AZ, Forty Seven to test triple immunotherapy combo for lymphoma

pharmatimes | May 13, 2019

AstraZeneca and Forty Seven are evaluating a new triple combination therapy clinical trial that has the potential to create additional opportunities to further optimise treatment for patients with diffuse large B-cell lymphoma. Forty Seven’s CD47 antibody, ‘5F9’, will be tested in combination with rituximab and Calquence (acalabrutinib) for the aggressive form of non-Hodgkin’s lymphoma (NHL). The study aims to build upon the promising results already reported from a Phase Ib study of 5F9 in combination with rituximab in NHL patients by including a third agent, acalabrutinib, to further optimise the treatment of patients. The collaboration will “expand the breadth of our 5F9 development program to include an additional triplet regimen, with the potential to offer patients a treatment option that is more easily administered and the benefit of multiple distinct approaches to treating cancer,” said Craig Gibbs, chief business officer at Forty Seven Inc.

Spotlight

Fascinating developments within the biopharmaceutical sector have been grabbing industry headlines for years now. The field is exciting and developing rapidly. However, the reality is that small, synthetic molecules remain critically important to both drug development pipelines and the market.

Spotlight

Fascinating developments within the biopharmaceutical sector have been grabbing industry headlines for years now. The field is exciting and developing rapidly. However, the reality is that small, synthetic molecules remain critically important to both drug development pipelines and the market.

Related News

PHARMACY MARKET

Rx Linc Partners with Scriptera to Enhance Pharmacies Bottomline

Rx Linc | October 08, 2021

Rx Linc, an emerging Business Intelligence pharmacy Switch network, and Scriptera, an organization whose mission is to create data opportunities for their health care partners, announced a strategic partnership that enables pharmacies to monetize their market-level data through a unique revenue sharing program. We are very excited and pleased to bring Scriptera's data platform and industry opportunities to Rx Linc's Switch Network. Rx Linc is focused on delivering data-driven solutions that provide value and opportunity to our pharmacy customers, By partnering with Scriptera, they fit directly into that mission where we now can monetize de-identified pharmacy claims data back to those that are producing the data daily. For too many years, pharmacy has been producing data that provides significant value to the healthcare ecosystem. It's exciting to be able to deliver value in monetizing this data utilization and at a NO cost program. - Josh Cline, Vice President of Rx Linc. Empower your data with a NO-cost program Scriptera is excited to partner with Rx Linc to bring our platform to their network at no cost, The core values of Scriptera and Rx Linc align perfectly as our core mission is to help see pharmacies succeed in such a challenging time. Scriptera unlocks the hidden value that independent pharmacies have been missing out on by empowering their data. - Kevin Laxer, founder of Scriptera. This partnership comes at a critical time in the pharmacy space as Rx Linc strives to deliver more viable revenue streams to pharmacies. Together, Scriptera and Rx Linc are committed to transforming how pharmacies can benefit from providing de-identified healthcare data. About Rx Linc Rx Linc is a Nationwide Switch network delivering data-driven solutions to their pharmacy customers. Since 1998, Rx Linc has been helping a wide range of pharmacies save time and money through data analysis and proactive outreach to minimize claim errors and maximize reimbursements. Rx Linc's data analytics combined with market intelligence improves pharmacy performance by identifying opportunities at every stage of the claims process. About Scriptera Scriptera creates data opportunities for all our partners in order to unlock more precise and faster insights than ever before. We specialize in solutions for pharmacies, wholesalers, manufacturers, and pharmacy companies. Scriptera's team has deep relationships with all these stakeholders to truly understand and identify their unmet needs.

Read More

PHARMACY MARKET

Lubrizol Life Science Launches Advanced, Natural Nutraceutical Solution to Support Mental Agility

Lubrizol Life Science | October 28, 2020

Lubrizol Life Science Health (LLS Health) launches ASTAGILE™ microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina. The two ingredients have been uniquely combined in a patent-pending product designed to promote mental agility and support healthy ageing for young and senior adults. Astaxanthin is a carotenoid found in freshwater microalgae, and spirulina is a type of algae. Both have numerous health promoting effects. To create the synergistic algae blend, LLS Health teamed with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology.

Read More

PHARMACY MARKET

Mallax acquires Sana Pharma Medical, Establishing a New Nordic Pharmaceutical Platform

Mallax | July 05, 2021

Mallax Pharmaceuticals AB has acquired Sana Pharma Medical AS, forming a new Nordic pharmaceutical platform. SPM, founded in Norway in 2014, is a rapidly growing OTC company with complete pharmaceutical infrastructure and Nordic distribution coverage. With the well-established brands such as Lunixen and Sedix and additional products based on the chemical melatonin, the Company has a leading position in the fast-growing sleep and anxiety sector. SPM is a well-resourced platform with about 15 FTEs that provides extensive in-house pharmaceutical expertise and experience to serve as an appealing basis for Mallax. Furthermore, the Company has a sizable and steadily growing pipeline of new products that will be released in the future years. Mallax was founded in 2020 by Impilo, a Nordic healthcare-focused investment firm, and Anders Larnholt, a seasoned pharma, and healthcare executive, with the long-term goal of creating a large and diverse platform with established pharmaceuticals and OTC products for customers and patients across Europe. Dr. Peter Sjöstrand, the former deputy CEO and CFO of Astra and the former Chairman of the Boards of Gambro and Meda, is named Chairman of the Board of Mallax as part of the transaction. About Mallax Mallax was founded in 2020 by Impilo and Anders Larnholt with the ambition of building a leading pharma company and investing significant capital and resources behind the right acquisition opportunities across Europe, with a wide size range for any individual deal ranging from EUR 10 million to EUR 300 million. Mallax's strategy is based on three pillars: sustainability, medical need, and profitable growth. Mallax currently has operations in all Nordic markets due to the acquisition of Sana Pharma Medical. About Impilo Impilo is a Nordic investment firm that makes long-term investments in healthcare companies involved in pharmaceuticals, medical technology, healthcare services, and other health-related sectors. Impilo seeks to enhance the value of its assets via long-term active ownership and generate consistent returns for its stakeholders. Impilo has a well-diversified investment portfolio and has raised over SEK 9 billion in capital from leading Nordic and international investors since its inception in 2017.

Read More